Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia, and Australia.
In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
NASP and Uncontrolled gout
Sobi hosted an investor conference call on 16 September to discuss the clinical program overview for NASP (previously known as SEL-212) and the uncontrolled gout disease landscape.
Loading...
Press releases
Upcoming events
Loading...